Critical Contrast: Trinity Biotech PLC (TRIB) and Quidel Corporation (QDEL)

Trinity Biotech PLC (NASDAQ: TRIB) and Quidel Corporation (NASDAQ:QDEL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitabiliy, earnings, analyst recommendations, risk, valuation, dividends and institutional ownership.

Valuation & Earnings

This table compares Trinity Biotech PLC and Quidel Corporation’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Trinity Biotech PLC $99.63 million 1.32 $7.90 million ($3.61) -1.64
Quidel Corporation $214.97 million 3.98 $39.80 million $0.10 257.43

Quidel Corporation has higher revenue and earnings than Trinity Biotech PLC. Trinity Biotech PLC is trading at a lower price-to-earnings ratio than Quidel Corporation, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

66.4% of Trinity Biotech PLC shares are owned by institutional investors. Comparatively, 89.6% of Quidel Corporation shares are owned by institutional investors. 12.7% of Trinity Biotech PLC shares are owned by company insiders. Comparatively, 22.0% of Quidel Corporation shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations for Trinity Biotech PLC and Quidel Corporation, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trinity Biotech PLC 0 1 0 0 2.00
Quidel Corporation 0 3 1 0 2.25

Quidel Corporation has a consensus target price of $24.67, indicating a potential downside of 4.17%. Given Quidel Corporation’s stronger consensus rating and higher probable upside, analysts clearly believe Quidel Corporation is more favorable than Trinity Biotech PLC.

Risk & Volatility

Trinity Biotech PLC has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Quidel Corporation has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500.


This table compares Trinity Biotech PLC and Quidel Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trinity Biotech PLC -98.39% 5.00% 2.63%
Quidel Corporation 1.83% 1.94% 1.02%


Quidel Corporation beats Trinity Biotech PLC on 11 of the 14 factors compared between the two stocks.

Trinity Biotech PLC Company Profile

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company’s products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Its products are classified as POC, emergency medicine, clinical laboratory and blood bank screening. Its POC brands include Uni-Gold and Recombigen. Emergency medicine diagnostics refer to its acute care testing, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Trinity Biotech supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. Trinity Biotech’s blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections.

Quidel Corporation Company Profile

Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers. Its diagnostic solutions aid in the detection and diagnosis of critical diseases and other medical conditions, including infectious diseases, women’s health, gastrointestinal diseases, autoimmune diseases, bone health and thyroid diseases. The Company provides diagnostic testing solutions under various brand names, including Quidel, QuickVue, QuickVue+, MicroVue, FreshCells, D3 FastPoint, Super E-Mix, ELVIS, Sofia, Quidel Molecular, Amplivue, Lyra and Thyretain.

Receive News & Ratings for Trinity Biotech PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech PLC and related companies with's FREE daily email newsletter.

Leave a Reply